Showing 21 - 40 results of 21,951 for search '(((( 5 non decrease ) OR ( 2 fold decrease ))) OR ( 50 ((mean decrease) OR (we decrease)) ))', query time: 0.66s Refine Results
  1. 21
  2. 22
  3. 23
  4. 24

    Annual treatment frequencies in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

    Published 2025
    “…(<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0332941#pone.0332941.g007" target="_blank">Fig 7</a>). Mean outpatient visits in the recurrence group decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, p < 0.001). …”
  5. 25
  6. 26
  7. 27
  8. 28
  9. 29
  10. 30
  11. 31
  12. 32

    Annual number of outpatient visits in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

    Published 2025
    “…<p>In the recurrence group, mean outpatient visits (± standard deviation) decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”
  13. 33
  14. 34
  15. 35
  16. 36
  17. 37
  18. 38
  19. 39

    FTY720 decreased viability, proliferation, and motility and induced apoptosis in human hepatoblastoma cells. by Laura L. Stafman (6577184)

    Published 2019
    “…<p>(A) Following 24 hours of treatment with FTY720, the viability of HuH6 cells measured using the alamarBlue cell viability assay was significantly decreased (LD<sub>50</sub> = 8.4 μM, p ≤ 0.05). (B) Following 24 hours of treatment with FTY720, the proliferation of HuH6 cells measured using the CellTiter 96 cell proliferation assay was significantly decreased (IC<sub>50</sub> = 6.4 μM, p ≤ 0.05). …”
  20. 40